U.S. Food and Drug Administration Approves IMBRUVICA™ (ibrutinib) as a Single
Agent for Patients with Mantle Cell Lymphoma Who Have Received at Least One
Corporate Conference Call Scheduled Today at 10:00 AM PT, November 13, 2013
SUNNYVALE, Calif., Nov. 13, 2013
SUNNYVALE, Calif., Nov. 13, 2013 /PRNewswire/ -- Pharmacyclics, Inc. (NASDAQ:
PCYC) today announced that the U.S. Food and Drug Administration (FDA) has
approved IMBRUVICA™ (ibrutinib) as a single agent for the treatment of
patients with mantle cell lymphoma (MCL) who have received at least one prior
therapy.^1 This indication is based on overall response rate (ORR). An
improvement in survival or disease-related symptoms has not been established.
IMBRUVICA is a new agent that inhibits the function of Bruton's tyrosine
kinase (BTK).^1 BTK is a key signaling molecule of the B-cell receptor
signaling complex that plays an important role in the survival of malignant B
cells.^2,3,4 IMBRUVICA blocks signals that stimulate malignant B cells to grow
and divide uncontrollably.^1,5
To view the multimedia assets associated with this release, please click:
The FDA granted IMBRUVICA Breakthrough Therapy Designation due to the ORR and
duration of response (DOR) seen in the Phase II study, PCYC-1104, and the
serious and life-threatening nature of MCL.
The approval was based on the results of a multi-center, international,
single-arm trial of 111 patients with previously treated mantle cell
lymphoma. Tumor response was assessed according to the revised International
Working Group (IWG) for non-Hodgkin lymphoma (NHL) criteria. The efficacy
results demonstrated a 65.8% overall response rate (95% CI: 56.2, 74.5);17%
of patients achieved a complete response and 49% of patients achieved a
partial response. The median duration of response was 17.5 months (95% CI:
15.8, not reached).
Safety was evaluated in the same 111 patients. The most common Grade 3 or 4
non-hematological adverse reactions (greater than or equal to5%) were:
pneumonia (7%), abdominal pain (5%), atrial fibrillation, diarrhea (5%),
fatigue (5%), and skin infections (5%). Five percent of patients had Grade 3
or higher bleeding events (subdural hematoma, gastrointestinal bleeding, and
hematuria). Treatment-emergent Grade 3 or 4 cytopenias (adverse reactions and
laboratory abnormalities combined) were reported in 41% of patients. The
Warnings and Precautions listed in the Prescribing Information include
hemorrhage, infections, myelosuppression, renal toxicity, second primary
malignancies and embryo-fetal toxicity.
Ten patients (9%) discontinued treatment due to adverse reactions in the
Adverse reactions leading to dose reduction occurred in 14% of patients.
The recommended dose in this patient population is 560 mg (four 140 mg
capsules) orally once daily.^1
IMBRUVICA is one of the first treatments to receive FDA approval via the
Breakthrough Therapy Designation pathway. Pharmacyclics completed its New Drug
Application submission to the FDA in late June 2013 and received approval just
over four months later.
"This is a meaningful day for previously treated mantle cell lymphoma
patients, who are in need of new treatment options," said Michael Wang, M.D.,
Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer
Center and lead investigator for the pivotal registration trial PCYC-1104.
"With IMBRUVICA, we now have an important new medicine that is a once-daily
oral therapy with a favorable risk-benefit profile."
IMBRUVICA is commercially available immediately.
"The approval of IMBRUVICA marks significant progress toward Pharmacyclics'
goal of serving as an ally to patients. After observing early signs of
efficacy and tolerability of IMBRUVICA four years ago, we single-mindedly
focused our attention on fully developing this medicine. We continue to
explore IMBRUVICA's potential to treat cancer patients in need. Presently we
are in the midst of investigating this medicine in numerous additional B-cell
malignancies with 37 clinical studies ongoing," said Bob Duggan, CEO and
Chairman of the Board of Pharmacyclics. "Today we celebrate the first approval
of IMBRUVICA. I would like to thank the patients and physicians for their
trust and participation in our clinical trials. We are very grateful to the
FDA for their collaboration and support, and a very big 'thank you' to the
entire Pharmacyclics & Janssen team who have tirelessly forwarded our mutual
vision and mission to serve as allies for patients and physicians in the fight
"Breakthrough Therapy Designation is intended to speed up the development and
review of treatments to help address serious or life-threatening diseases. It
is gratifying to see this early example of the new pathway meeting its
intention – getting a promising treatment to patients who are waiting for new
options," said Dr. Ellen Sigal, chair and founder of Friends of Cancer
Research, a think tank and advocacy organization based in Washington, DC.
Corporate Conference Call
The Company will hold a conference call today at10:00 AM PT. To participate
in the conference call, please dial 1-877-303-7908 for domestic callers and
1-678-373-0875 for international callers and use the conference ID number
11347949. To access the live audio broadcast or the subsequent archived
recording, log on to http://ir.pharmacyclics.com/events.cfm. To access a
replay of the call please dial 1-855-859-2056 for domestic callers and
1-404-537-3406 for international callers and use the conference ID number:
11347949. The archived version of the webcast and conference call will be
available for 30 days on the Investor Relations section of the Company's Web
site at http://www.pharmacyclics.com.
During this call, the Company will provide detailed information on the
IMBRUVICA patient assistance, availability and other support programs.
INDICATION - IMBRUVICA (ibrutinib) is indicated for the treatment of patients
with mantle cell lymphoma (MCL) who have received at least one prior therapy.
This indication is based on overall response rate. An improvement in survival
or disease-related symptoms has not been established.
IMPORTANT SAFETY INFORMATION
WARNINGS AND PRECAUTIONS
Hemorrhage - 5% of patients with MCL hadgreater than or equal to Grade 3
bleeding events (subdural hematoma, gastrointestinal bleeding, and hematuria).
Bleeding events including bruising of any grade occurred in 48% of patients
with MCL treated with 560 mg daily. The mechanism for the bleeding events is
not well understood. Consider the benefit-risk of ibrutinib in patients
requiring antiplatelet or anticoagulant therapies and the benefit-risk of
withholding ibrutinib for at least 3 to 7 days pre and post-surgery depending
upon the type of surgery and the risk of bleeding.
Infections - Fatal and non-fatal infections have occurred. At least 25% of
patients with MCL had infectionsgreater than or equal toGrade 3, according
to NCI Common Terminology Criteria for Adverse Events (CTCAE). Monitor
patients for fever and infections and evaluate promptly.
Myelosuppression - Treatment-emergent Grade 3 or 4 cytopenias were reported in
41% of patients. These included neutropenia (29%), thrombocytopenia (17%) and
anemia (9%). Monitor complete blood counts monthly.
Renal Toxicity - Fatal and serious cases of renal failure have occurred.
Treatment-emergent increases in creatinine levels up to 1.5 times the upper
limit of normal occurred in 67% of patients and from 1.5 to 3 times the upper
limit of normal in 9% of patients. Periodically monitor creatinine levels.
Second Primary Malignancies - Other malignancies (5%) have occurred in
patients with MCL who have been treated with IMBRUVICA, including skin cancers
(4%) and other carcinomas (1%).
Embryo-Fetal Toxicity - Based on findings in animals, IMBRUVICA can cause
fetal harm when administered to a pregnant woman. Advise women to avoid
becoming pregnant while taking IMBRUVICA. If this drug is used during
pregnancy or if the patient becomes pregnant while taking this drug, the
patient should be apprised of the potential hazard to a fetus.
ADVERSE REACTIONS - The most commonly occurring adverse reactions (greater
than or equal to 20%) in the clinical trial were thrombocytopenia*, diarrhea
(51%), neutropenia*, anemia*, fatigue (41%), musculoskeletal pain (37%),
peripheral edema (35%), upper respiratory tract infection (34%), nausea (31%),
bruising (30%), dyspnea (27%), constipation (25%), rash (25%), abdominal pain
(24%), vomiting (23%) and decreased appetite (21%).
*Treatment-emergent decreases (all grades) of platelets (57%), neutrophils
(47%) and hemoglobin (41%) were based on laboratory measurements and adverse
The most common Grade 3 or 4 non-hematological adverse reactions (greater than
or equal to 5%) were pneumonia (7%), abdominal pain (5%), atrial fibrillation,
diarrhea (5%), fatigue (5%), and skin infections (5%). Treatment-emergent
Grade 3 or 4 cytopenias were reported in 41% of patients.
Ten patients (9%) discontinued treatment due to adverse reactions in the trial
The most frequent adverse reaction leading to treatment discontinuation was
subdural hematoma (1.8%). Adverse reactions leading to dose reduction occurred
in 14% of patients.
CYP3A Inhibitors - Avoid concomitant administration with strong or moderate
inhibitors of CYP3A. If a moderate CYP3A inhibitor must be used, reduce the
CYP3A Inducers - Avoid co-administration with strong CYP3A inducers.
SPECIAL POPULATIONS - Hepatic Impairment - Avoid use in patients with baseline
For the full prescribing information, visit
Access to IMBRUVICA
Patients who are prescribed IMBRUVICA can receive access support through
several distinct programs:
oThe YOU&i Start™ program enables eligible patients who have been
prescribed IMBRUVICA for the FDA-approved indication and are experiencing
insurance coverage delays, to access free product for a limited period of
time, if they meet certain requirements. In addition, our YOU&i Access
service center is set up to help patients ensure that all access-related
administration is properly handled.
oThe YOU&i Access™ Instant Savings Program helps commercially insured
patients who have difficulties with out-of-pocket expenses for IMBRUVICA.
Eligible patients may receive support to reduce their monthly
out-of-pocket costs to $25.
oPatients who are deemed uninsured and eligible, and who qualify based on
financial need, can access IMBRUVICA through the Johnson & Johnson Patient
Assistance Foundation (JJPAF), an independent non-profit organization to
which Pharmacyclics makes donations.
oPharmacyclics will also support third party foundations, organizations and
other efforts to help patients in need get access to appropriate care.
More information about these robust patient access programs is accessible at
1-877-877-3536 or at www.IMBRUVICA.com.
"Pharmacyclics is committed to supporting patients and making access to
IMBRUVICA simple and convenient for them," said Duggan. "We have designed the
YOU&i Access program to provide sufficient aid so that all eligible patients,
including those facing financial or other obstacles, will have direct access
to IMBRUVICA for the duration of their therapy."
About Mantle Cell Lymphoma (MCL)
B cells are the immune cells in the body that are responsible for producing
antibodies to fight infections and provide long term immunity. MCL is a blood
cancer of the B cells; it is an aggressive type of B-cell non-Hodgkin lymphoma
(NHL) that usually occurs in older adults.^6 The disease typically involves
the lymph nodes, but can spread to other tissues, such as bone marrow, liver,
spleen, and gastrointestinal tract. Patients survive an average of five
years.^7 MCL is classified as an orphan or rare disease, meaning it affects
fewer than 200,000 Americans.^8
IMBRUVICA is indicated for the treatment of patients with mantle cell lymphoma
who have received at least one prior therapy.^1 This indication is based on
overall response rate (ORR). An improvement in survival or disease-related
symptoms has not been established. For more information about IMBRUVICA,
including the full prescribing information, please visit www.IMBRUVICA.com.
IMBRUVICA is a first in class, oral therapy and is a new agent that inhibits a
protein called Bruton's tyrosine kinase (BTK).^1 BTK is a key signaling
molecule of the B-cell receptor signaling complex that plays an important role
in the survival of malignant B cells.^2,3,4 IMBRUVICA blocks signals that tell
malignant B cells to grow and divide uncontrollably.^1,5 It is one of the
first medicines to file for FDA approval via the new Breakthrough Therapy
Designation pathway, enabling Pharmacyclics to rapidly bring this medicine to
patients in need.
To date, nine Phase III trials have been initiated with ibrutinib and a total
of 37 trials are currently registered on www.clinicaltrials.gov. Janssen and
Pharmacyclics entered a collaboration and license agreement in December 2011
to co-develop and co-commercialize IMBRUVICA.
Pharmacyclics^® is a biopharmaceutical company focused on developing and
commercializing innovative small-molecule drugs for the treatment of cancer
and immune mediated diseases. Our mission and goal is to build a viable
biopharmaceutical company that designs, develops and commercializes novel
therapies intended to improve quality of life, increase duration of life and
resolve serious unmet medical healthcare needs; and to identify promising
product candidates based on scientific development and administrational
expertise, develop our products in a rapid, cost-efficient manner and pursue
commercialization and/or development partners when and where appropriate.
Pharmacyclics markets IMBRUVICA and has three product candidates in clinical
development and several preclinical molecules in lead optimization. The
company is committed to high standards of ethics, scientific rigor, and
operational efficiency as it moves each of these programs to viable
Pharmacyclics is headquartered in Sunnyvale, California and is listed on
NASDAQ under the symbol PCYC. To learn more about how Pharmacyclics advances
science to improve human healthcare visit us at www.pharmacyclics.com.
NOTE: This announcement may contain forward-looking statements made in
reliance upon the safe harbor provisions of Section 27A of the Securities Act
of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934,
as amended, including statements, among others, relating to our future capital
requirements, including our expected liquidity position and timing of the
receipt of certain milestone payments, and the sufficiency of our current
assets to meet these requirements, our future results of operations, our
expectations for and timing of ongoing or future clinical trials and
regulatory approvals for any of our product candidates, and our plans,
objectives, expectations and intentions. Because these statements apply to
future events, they are subject to risks and uncertainties. When used in this
announcement, the words "anticipate", "believe", "estimate", "expect",
"expectation", "goal", "should", "would", "project", "plan", "predict",
"intend", "target" and similar expressions are intended to identify such
forward-looking statements. These forward-looking statements are based on
information currently available to us and are subject to a number of risks,
uncertainties and other factors that could cause our actual results,
performance, expected liquidity or achievements to differ materially from
those projected in, or implied by, these forward-looking statements. Factors
that may cause such a difference include, without limitation, our need for
substantial additional financing and the availability and terms of any such
financing, the safety and/or efficacy results of clinical trials of our
product candidates, our failure to obtain regulatory approvals or comply with
ongoing governmental regulation, our ability to commercialize, manufacture and
achieve market acceptance of any of our product candidates, for which we rely
heavily on collaboration with third parties, and our ability to protect and
enforce our intellectual property rights and to operate without infringing
upon the proprietary rights of third parties. Although we believe that the
expectations reflected in the forward-looking statements are reasonable, we
cannot guarantee future results, performance or achievements and no assurance
can be given that the actual results will be co nsistent with these
forward-looking statements. For more information about the risks and
uncertainties that may affect our results, please see the Risk Factors section
of our filings with the Securities and Exchange Commission, including our
transition report on Form 10-K for the six month period ended December 31,
2012 and quarterly reports on Form 10-Q. We do not intend to update any of the
forward-looking statements after the date of this announcement to conform
these statements to actual results, to changes in management's expectations or
otherwise, except as may be required by law.
Senior Director, Public Relations and Corporate Communications
Senior Vice President, Investor Relations
U.S. Medical Information, Pharmacyclics
^1 IMBRUVICA Prescribing Information, November 2013
^2 Buggy JJ and Elias L. Bruton tyrosine kinase (BTK) and its role in B-cell
malignancy. Int Rev Immunol. 2012;31:119-132.
^3 Woyach JA, Johnson AJ, and Byrd JC. The B-cell receptor signaling pathway as a therapeutic target in CLL. Blood.
^4 Davis RE, Ngo VN, Lenz G, et al. Chronic active B-cell receptor signaling in diffuse large B-cell lymphoma.
^5 Cleveland Clinic. Top 10 Medical Innovations For 2014. Video. Available from:
^6Cancer.net. "Lymphoma – Non-Hodgkin". http://www.cancer.net/cancer-types/lymphoma-non-hodgkin/subtypes. Accessed
^7 Leukemia and Lymphoma Society. Mantle Cell Lymphoma Facts. Available from:
^8 National Organization for Rare Disorders. "Rare Disease Information". Available from:
http://www.rarediseases.org/rare-disease-information/rare-disease-information. Accessed September 2013.
SOURCE Pharmacyclics, Inc.
Press spacebar to pause and continue. Press esc to stop.